<DOC>
	<DOCNO>NCT00323700</DOCNO>
	<brief_summary>To determine clinically statistically significant difference OROS-MPH IR MPH ADHA ODD symptom parent complete SNAP-IV . It hypothesize OROS-MPH superior improve symptom outcome overall , remission rate , functional improvement , quality life persistence medication time .</brief_summary>
	<brief_title>A Naturalistic Prospective Study Treatment Effectiveness Attention-Deficit/Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description>This one-year prospective observational study design evaluate compare outcomes effectiveness OROS-MPH IR MPH ADHA ODD symptom ADHD Clinic British Columbia Children 's Women 's Health Centre . A practical clinical trial valuable potential provide u information represent actual outcome real setting . The primary objective study analyze treatment outcome ADHD patient condition routine clinical practice . Patients , therefore , treat accord current practice participate physician , exception several additional rating scale SNAP-IV , Strengths Difficulties Questionnaire , WEISS Functional Impairment Rating Scale ( WFIRS ) -Parent , Child Health Illness Profile ( CHIP ) , EQ-5D , Parent/Caregiver Questionnaire , ADHD Side Effect Checklist , Adolescent Diversion Questionnaire , Adaptive Behavior Assessment System-Second Edition ( ABAS-2 ) Clinic Global Impressions . Patients assess baseline 12 month regardless whether original treatment continue . If patient terminates study early , assessment normally collect end study collect time termination . Only patient pre post data include analysis . Results study expect make breakthrough treatment ADHD practice ; , particularly , information come study currently available research .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<criteria>1 . Patients age 6 18 . 2 . Enrolled school least 1 school year remain completion high school . 3 . Current drug therapy either IR MPH OROS MPH . 1 . Parent/caregiver unable unwilling provide write informed consent . 2 . Child unable unwilling provide assent ( child age 7 year ) . 3 . Parent/caregiver unable unwilling complete questionnaire . 4 . Child unable unwilling complete questionnaire ADHD consider clinician secondary another serious disorder personality disorder , substance abuse , bipolar disorder , autism , mental handicap . 5 . Participation another treatment study .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>ADHD</keyword>
	<keyword>Effectiveness</keyword>
	<keyword>ODD</keyword>
</DOC>